| Literature DB >> 28018334 |
Aimi Hanafi1, Woon Ching Lee1, Mun Fai Loke2, Xinsheng Teh1, Ain Shaari1, Mojdeh Dinarvand1, Philippe Lehours3, Francis Mégraud3, Alex Hwong Ruey Leow4, Jamuna Vadivelu1, Khean Lee Goh4.
Abstract
Antibiotic resistance in bacteria incurs fitness cost, but compensatory mechanisms may ameliorate the cost and sustain the resistance even under antibiotics-free conditions. The aim of this study was to determine compensatory mechanisms of antibiotic resistance in H. pylori. Five strains of levofloxacin-sensitive H. pylori were induced in vitro to develop resistance. In addition, four pairs of metronidazole-sensitive and -resistant H. pylori strains were isolated from patients carrying dual H. pylori populations that consist of both sensitive and resistant phenotypes. Growth rate, virulence and biofilm-forming ability of the sensitive and resistant strains were compared to determine effects of compensatory response. Proteome profiles of paired sensitive and resistant strains were analyzed by liquid chromatography/mass spectrophotometry (LC/MS). Although there were no significant differences in growth rate between sensitive and resistant pairs, bacterial virulence (in terms of abilities to induce apoptosis and form biofilm) differs from pair to pair. These findings demonstrate the complex and strain-specific phenotypic changes in compensation for antibiotics resistance. Compensation for in vitro induced levofloxacin resistance involving mutations of gyrA and gyrB was functionally random. Furthermore, higher protein translation and non-functional protein degradation capabilities in naturally-occuring dual population metronidazole sensitive-resistant strains may be a possible alternative mechanism underlying resistance to metronidazole without mutations in rdxA and frxA. This may explain the lack of mutations in target genes in ~10% of metronidazole resistant strains.Entities:
Keywords: Helicobacter pylori; antibiotic resistance; bacterial fitness; levofloxacin; metronidazole; proteome
Year: 2016 PMID: 28018334 PMCID: PMC5157799 DOI: 10.3389/fmicb.2016.02015
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Figure 1. aUM276 and UM276L (levofloxacin-sensitive and resistant), UM163M, UM303M, UM400M, UM443M have naturally-occuring resistance to metronidazole. bUM229 and UM229L (levofloxacin-sensitive and resistant) has naturally-occuring resistance to clarithromycin. cResistant to metronidazole, levofloxacin, and/or clarithromycin.
MICs of .
| UM137 and UM137L | Levofloxacin-resistance (induced) | 0.064 | >32 |
| UM171 and UM171L | Levofloxacin-resistance (induced) | 0.094 | >32 |
| UM229 | Levofloxacin-resistance (induced) | 0.032 | >32 |
| UM233 and UM233L | Levofloxacin-resistance (induced) | 0.125 | >32 |
| UM276 | Levofloxacin-resistance (induced) | 0.125 | >32 |
| UM163 and UM163M | Metronidazole-resistance (naturally-occurring dual population) | 0.5 | >256 |
| UM303 and UM303M | Metronidazole-resistance (naturally-occurring dual population) | 0.75 | >256 |
| UM400 and UM400M | Metronidazole-resistance (naturally-occurring dual population) | 0.5 | >256 |
| UM443 and UM443M | Metronidazole-resistance (naturally-occurring dual population) | 0.75 | >256 |
UM229 and UM229L (levofloxacin-sensitive and resistant) has naturally-occuring resistance to clarithromycin.
UM276 and UM276L (levofloxacin-sensitive and resistant), UM163M, UM303M, UM400M, UM443M have naturally-occuring resistance to metronidazole.
Figure 2RAPD-PCR typing of (A) levofloxacin-induced H. pylori UM137 strains 1–8 sensitive, 9–12 resistant (B) metronidazole dual population of H. pylori UM163 strains 13–19 sensitive, 20–22 resistant. Primers used were 1254 and 1281, and M: 1 kb DNA ladder.
Figure 3Growth curves of (A) UM137 (B) UM171 (C) UM229 (D) UM233 (E) UM276 (F) UM163 (G) UM303 (H) UM400 (I) UM443 H. pylori strains. Data represent mean ± SEM (n = 3).
Fold differences of the apoptotic AGS cells population induced by .
| UM137 and UM137L | 1.33 |
| UM171 and UM171L | 1.00 |
| UM229 and UM229L | 1.33 |
| UM233 and UM233L | 0.83 |
| UM276 and UM276L | 1.25 |
| UM163 and UM163M | 0.33 |
| UM303 and UM303M | 0.25 |
| UM400 and UM400M | 3.50 |
| UM443 and UM443M | 1.50 |
Fold difference <0.5 and >2.0 is considered to have undergone significant change.
Average biofilm formation of .
| UM137 | 0.744 | 0.240 |
| UM137L | 0.178 | |
| UM171 | 0.796 | 0.777 |
| UM171L | 0.618 | |
| UM229 | 0.039 | 3.259 |
| UM229L | 0.126 | |
| UM233 | 0.158 | 0.184 |
| UM233L | 0.029 | |
| UM276 | 0.092 | 1.348 |
| UM276L | 0.124 | |
| UM163 | 0.420 | 0.723 |
| UM163M | 0.304 | |
| UM303 | 0.098 | 1.058 |
| UM303M | 0.104 | |
| UM400 | 0.020 | 4.627 |
| UM400M | 0.091 | |
| UM443 | 0.258 | 2.004 |
| UM443M | 0.518 |
High-level biofilm former strains.
Figure 4Amino acid sequences of levofloxacin resistance-associated gene regions: (A) gyrA, (B) gyrB, and metronidazole resistance-associated gene regions: (C) rdxA, (D) frxA of H. pylori strains. gyrA and gyrB sequences were compared to UM038 strain (positive gyrA mutation), and rdxA and frxA sequences were compared to a reference strain, 26695. Positions of expected mutations associated with levofloxacin are in box outlines, and positions of variations of mutation in either antibiotic-resistant strains are in gray boxes.
Proteins of significant association with resistance to metronidazole, levofloxacin, and/or clarithromycin in all of the 18 .
| UvrB | UvrABC system protein B | Levofloxacin | 0.014 |
| Jhp_0525 | Putative protein | Levofloxacin | 0.031 |
| Jhp_0602 | Putative processing protease | Levofloxacin | 0.031 |
| Jhp_0260 | Putative protein | Levofloxacin | 0.032 |
| CarB | Carbamoyl-phosphate synthase large chain | Levofloxacin | 0.033 |
| ClpP | Chaperone protein | Metronidazole | 0.007 |
| Jhp_0892 | Putative protein | Metronidazole | 0.007 |
| SerA (Jhp_0984) | D-3-phosphoglycerate dehydrogenase | Metronidazole | 0.007 |
| Efp (Jhp_0163) | Elongation factor P | Metronidazole | 0.022 |
| HypB (Jhp_0837) | Hydrogenase/urease nickel incorporation protein HypB | Metronidazole | 0.022 |
| IleS (Jhp_1317) | Isoleucine-tRNA ligase | Metronidazole | 0.022 |
| ProS (Jhp_0067) | Urease subunit beta | Metronidazole | 0.022 |
| RplF (Jhp_1224) | 50S ribosomal protein L6 | Metronidazole | 0.022 |
| RpsS (Jhp_1235) | 30S ribosomal protein S19 | Metronidazole | 0.022 |
| PyrF (Jhp_0005) | Orotidine 5′-phosphate decarboxylase | Metronidazole | 0.031 |
| RpsI (Jhp_0076) | 30S ribosomal protein S9 | Metronidazole | 0.031 |
| Jhp_0844 | Flagellar basal body protein | Metronidazole, levofloxacin | 0.042 |
| Jhp_1071 | Putative protein | Metronidazole, levofloxacin | 0.042 |
| Jhp_1303 | Putative protein | Metronidazole, levofloxacin | 0.042 |
| CysS (Jhp_0818) | Cysteine-tRNA ligase | Metronidazole, levofloxacin | 0.042 |
These proteins were up-regulated in the levofloxacin and metronidazole resistant H. pylori strains.
Figure 5STRING protein-protein interaction network of proteins from PEAKS refined data. The gene names correspond with the proteins that were recovered from (A) levofloxacin and (B) metronidazole-sensitive and resistant strains.
Proteins with differential expression among nine pairs of levofloxacin and metronidazole-resistant and sensitive strains.
| Aminoacyl-tRNA editing activity, ATP binding, proline-tRNA ligase activity | Prolyl-tRNA aminoacylation | Aminoacyl-tRNA biosynthesis (970) | |
| Aminoacyl-tRNA editing activity, ATP binding, isoleucine-tRNA ligase activity, zinc ion binding | Isoleucyl-tRNA aminoacylation | Aminoacyl-tRNA biosynthesis (970) | |
| ATP binding, cysteine-tRNA ligase activity, zinc ion binding | Cysteinyl-tRNA aminoacylation | Aminoacyl-tRNA biosynthesis (970) | |
| rRNA binding, structural constituent of ribosome | Translation | Ribosome (3010) | |
| rRNA binding, structural constituent of ribosome | Translation | Ribosome (3010) | |
| Structural constituent of ribosome | Translation | Ribosome (3010) | |
| Amino acid binding, NAD binding, phosphoglycerate dehydrogenase activity | L-serine biosynthetic process | Metabolic pathways (1100) | |
| Orodotine-5′-phosphate decarboxylase activity | “ | Metabolic pathways (1100) | |
| Bacterial-type flagellum-dependent cell motility | Flagellar assembly (2040) |
These proteins were up-regulated in the levofloxacin and metronidazole resistant H. pylori strains.